Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index; 41 of the 65 sources its claims cite were checked for support.

Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study

Open access
Bepo, Lurit, Nguyen, Oanh K., Makam, Anil N. · 2024 · Journal of General Internal Medicine

Abstract

This nationally representative cohort study assessed how racial/ethnic differences in SGLT2i and GLP-1RA use vary by payer after adjustment for socioeconomic and healthcare access factors.

Overview

CoChat Summary

TL;DR

In a nationally representative cross-sectional analysis of adults with diabetes, racial/ethnic disparities in SGLT2i/GLP1ra use varied by insurance type and were largest among people with private insurance. Medicaid enrollees had the lowest overall use, but no statistically significant racial/ethnic disparity.

Key findings

  • The study included 4,997 adults, representing about 24.8 million US adults annually with diabetes; mean age was 63.6 years, 48.8% were female, 33.5% had private insurance, 56.8% Medicare, and 9.8% Medicaid.
  • Overall, 12.9% used at least one SGLT2i or GLP1ra; use was highest with private insurance (17.3%), then Medicare (10.9%), and lowest with Medicaid (9.9%).
  • In the fully adjusted model, White individuals with private insurance had higher use than non-White individuals (16.1% vs 8.3%, p < 0.001); the disparity was smaller for Medicare (14.7% vs 11.0%, p = 0.04) and not significant for Medicaid (10.0% vs 9.0%, p = 0.74).
  • In unadjusted models, White vs non-White odds of medication use were OR 2.42 (95% CI 1.65–3.53) for private insurance and OR 1.43 (95% CI 1.01–2.01) for Medicare.

Methods

  • Observational cross-sectional analysis of 2018–2019 MEPS data; participants were adults ≥ 18 years with self-reported diabetes.
  • Insurance was classified as private, Medicare, or Medicaid based on ≥ 7 months of coverage; the outcome was receipt of ≥ 1 SGLT2i or GLP1ra in a calendar year.
  • The main analysis used survey-weighted multivariable logistic regression with a race/ethnicity × payer interaction, then sequentially adjusted for cardiovascular risk, socioeconomic status, and healthcare access factors.

Limitations

  • The paper states it could not further disaggregate race/ethnicity in adjusted analyses because of insufficient sample size, and could not capture within-payer variation in formularies or cost-sharing.
  • It also states it could not distinguish type 1 from type 2 diabetes, and lacked reliable data on some comorbidities, labs, and insulin use.
  • Evident from the text: because the study is cross-sectional and based on self-reported survey data, it cannot establish causality and may be subject to measurement limitations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11606-024-08961-x

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Predicted probabilities of any SGLT2i and GLP1ra medication use. Panel A: Base model. Panel B: Model adjusted for cardiovascular risk factors. Panel C: Fully adjusted model. Abbreviations: CI, 95% confidence interval; GLP1ra, glucagon-like peptide-1 receptor agonist; SGLT2i, sodium-glucose co-transporter-2 inhibitor. The three panels in this figure show the predicted probability of any SGLT2i and GLP1ra medication use in (A) the base model; (B) the base model adjusted for age, sex, and diagnosis of CAD, hypertension, and high cholesterol; and (C) the base + cardiovascular risk models further adjusted for education, family income as a percent of federal poverty level, marital status, presence of usual source of care, and managed care plan.
Figure 1. Predicted probabilities of any SGLT2i and GLP1ra medication use. Panel A: Base model. Panel B: Model adjusted for cardiovascular risk factors. Panel C: Fully adjusted model. Abbreviations: CI, 95% confidence interval; GLP1ra, glucagon-like peptide-1 receptor agonist; SGLT2i, sodium-glucose co-transporter-2 inhibitor. The three panels in this figure show the predicted probability of any SGLT2i and GLP1ra medication use in (A) the base model; (B) the base model adjusted for age, sex, and diagnosis of CAD, hypertension, and high cholesterol; and (C) the base + cardiovascular risk models further adjusted for education, family income as a percent of federal poverty level, marital status, presence of usual source of care, and managed care plan.CC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 2 Not valid · 3 Not checked · 45 Own results and interpretations

28 more claims · 4 with their cited sources checked

Create a free account to see all 64 claims and to verify the 5 references still open.

See all claims — free account
  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 21

Create a free account to see these claims.

Citations

Cites

Show all 36 references

Cited by

See all 20

Metadata

Authors
Bepo, L., Nguyen, O. K., & Makam, A. N.
Affiliations
San Francisco General Hospital (US)
Corresponding author
Bepo, Lurit
Venue
Journal of General Internal Medicine
Published
2024-07-31
Volume
39
Issue
15
Pages
2987-2994
ISSN
  • 0884-8734 (ISSN-L)
  • 1525-1497
OpenAlex
W4401169921
Cited by
20
References
36
Citations by year
2026: 10 · 2025: 10
FWCI
6.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of General Internal Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
Funders
  • Health Resources and Services Administration (T32HP19025)
  • National Heart, Lung, and Blood Institute (K23HL133441)
  • National Institute on Aging (K23AG052603)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Social Sciences › Health › Health disparities and outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, racial and ethnic disparities, SGLT2 inhibitors, GLP-1 receptor agonists, insurance coverage, Medicare, Medicaid, private insurance, access to medicines, cost sharing, prior authorization, formulary restrictions, Hispanic population, prescription rates, Medical Expenditure Panel Survey, health equity, cardiovascular risk reduction, health care access, socioeconomic factors
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Female, Medicare, Humans, Hypoglycemic Agents, Insurance, Health, Male, Medicaid, Middle Aged, United States, Cohort Studies, Insurance Coverage, Healthcare Disparities

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study. https://app.cochat.ai/papers/10.1007/s11606-024-08961-x
The paper
Bepo, L., Nguyen, O. K., & Makam, A. N. (2024). Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-024-08961-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.